hair loss semaglutide vs tirzepatide The risk of in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest. More details at the 🔗 in Hair loss with GLP-1 drugs

& Nielsen, O

Approved by the FDA in 2017 for type 2 diabetes, Ozempic is shown to have significant benefits for A1C reductions (nearly 2%) and weight loss

While tirzepatide, still somewhat newer, is showing its potential in not just managing blood sugar but also aiding in weight loss and possibly improving heart health

Characterizing dual GLP-1/GIP receptor agonists demands tools that resolve receptor engagement with specificity and spatial resolution that conventional approaches cannot provide

Weekly formulations may improve adherence compared to daily injections for some patients

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: systematic review and meta-analysis